COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,363 Articles (22,803 medRxiv, 8,560 bioRxiv)

Most recent first Previous |  Page 2347: Articles 23461-23470  | Next

A Syndromic Surveillance Tool to Detect Anomalous Clusters of COVID-19 Symptoms in the United States
Güemes, A., Ray, S., Aboumerhi, K., Desjardins, M. R., Kvit, A., Corrigan, A. E., Fries, B., Shields, T., Stevens, R. D., Curriero, F. C., Etienne-Cummings, R.
10.1101/2020.08.18.20177295 — Posted: 2020-08-21
Comprehensive Surveillance of SARS-CoV-2 Spread Using Wastewater-based Epidemiology Studies
Manupati, H., Kiran, U., Kuncha, S. K., Kopperi, H., C.G., G., S., V. M., Mishra, R. K.
10.1101/2020.08.18.20177428 — Posted: 2020-08-21 Discussion: Onsite
The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals.
Mateos Gonzalez, M., Sierra Gonzalo, E., Casado Lopez, I., Arnalich Fernandez, F., Beato Perez, J. L., Monge Monge, D., Vargas Nunez, J. A., Garcia Fenoll, R., Suarez Fernandez, C., Freire Castro, S. J., Mendez Bailon, M., Perales Fraile, I., Madrazo, M., Pesqueira Fontan, P. M., Magallanes Gamboa, J. O., Gonzalez Garcia, A., Crestelo Vieitez, A., Fonseca Aizpuru, E. M., Aranguren Arostegui, A., Coduras Erdozain, A., Martinez Cilleros, C., Loureiro Amigo, J., Epelde, F., Lumbreras Bermejo, C., Anton Santos, J. M.
10.1101/2020.08.18.20172874 — Posted: 2020-08-21
Comparisons of COVID-19 dynamics in the different countries of the World using Time-Series clustering
Alvarez, E., Brida, J. G., Limas, E.
10.1101/2020.08.18.20177261 — Posted: 2020-08-21
Ubiquitous Forbidden Order in R-group classified protein sequence of SARS-CoV-2 and other viruses
Pratibha, P., Shaju, C., Kamal, K.
10.1101/2020.08.21.261289 — Posted: 2020-08-21
Astodrimer sodium, dendrimer antiviral, inhibits replication of SARS-CoV-2 in vitro
Paull, J. R. A., Castellarnau, A., Luscombe, C. A., Fairley, J. K., Heery, G. P.
10.1101/2020.08.20.260190 — Posted: 2020-08-21
Morphometry of SARS-CoV and SARS-CoV-2 particles in ultrathin sections of infected Vero cell cultures.
Laue, M., Kauter, A., Hoffmann, T., Michel, J., Nitsche, A.
10.1101/2020.08.20.259531 — Posted: 2020-08-21 Discussion: Onsite
COVID-19 and Cholinergic Anti-inflammatory Pathway: In silico Identification of an Interaction between alpha7 Nicotinic Acetylcholine Receptor and the Cryptic Epitopes of SARS-CoV and SARS-CoV-2 Spike Glycoproteins
Lagoumintzis, G., Chasapis, C., Alexandris, N., Tzartos, S., Eliopoulos, E., Farsalinos, K., Poulas, K.
10.1101/2020.08.20.259747 — Posted: 2020-08-21
Characterization of cells susceptible to SARS-COV-2 and methods for detection of neutralizing antibody by focus forming assay
Stone, E. T., Geerling, E., Steffen, T. L., Hassert, M., Dickson, A., Spencer, J. F., Toth, K., DiPaolo, R. J., Brien, J. D., Pinto, A. K.
10.1101/2020.08.20.259838 — Posted: 2020-08-21
Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation
Lapointe, C. P., Grosely, R., Johnson, A. G., Wang, J., Fernandez, I. S., Puglisi, J. D.
10.1101/2020.08.20.259770 — Posted: 2020-08-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).